COSCIENS Biopharma (CSCI)announced the appointment of Anna Biehn as Chief Executive Officer, CEO, effective May 5, 2025. Biehn is a global general management and marketing executive with over 25 years of experience across the consumer products and biosciences industries. She joins COSCIENS having most recently served as the Chief Financial Officer of NuTek Natural Ingredients, a clean-label and plant-based food ingredient company.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSCI:
- COSCIENS Biopharma Reports Revenue Growth and Strategic Repositioning
- COSCIENS Biopharma Faces Management Cease Trade Order Amid Filing Delays
- COSCIENS Biopharma Faces Potential Delay in Year-End Filings Due to Merger Complexities
- Cosciens Biopharma announces possible delay in filing 2024-end documents
- COSCIENS Biopharma Advances Avenanthramides to Phase 2a Trial